Business Wire

Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated ...

– In Ongoing Phase 1/2 Study, Single Subcutaneous Doses of ALN-CC5 Achieve Potent, Statistically Significant, and Highly Durable C5 Knockdown of up to 96% – – After Single Dose, ALN-CC5 Also Achieves ...
Business Wire

Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)

Complement component C5, which is predominantly expressed in liver cells, is a genetically and clinically validated target; loss of function human mutations are associated with an attenuated immune ...
MedPage Today

PNH Treatment with Complement Inhibition

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
JSTOR Daily

Human Genetic Deficiencies Reveal the Roles of Complement in the Inflammatory Network: Lessons from Nature

Complement component C5 is crucial for experimental animal inflammatory tissue damage; however, its involvement in human inflammation is incompletely understood. The responses to Gram-negative ...
FiercePharma

The Aplastic Anemia & MDS International Foundation supports Amyndas Pharmaceuticals’ novel complement inhibitor AMY-101

Amyndas Pharmaceuticals S.A. is pleased to announce today that the Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas' lead candidate AMY-101, ...